Nuvation Bio Inc. (NUVB)
NYQ · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Nuvation Bio Inc. — ARS Filing
# 🧾 What This Document Is This is Nuvation Bio's **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "check-in" with its owners (the shareholders). It's a comprehensive report that combines financial data, business highlights, and future plans into one document, going beyo
NUVB Sets 2026 Annual Vote on Three Director Nominees
# 🧾 What This Document Is This is Nuvation Bio’s **DEF 14A Proxy Statement**, a formal invitation and explanation for its **2026 Annual Meeting of Stockholders**. It outlines proposals for shareholder votes, details on director nominees, executive compensation, and governance practices. Sharehold
SEC filings
All filings →Insider trades
All insider trades →Nuvation Bio Inc. has no reported insider trades in the last 90 days.